间质性肺疾病(ILD)是一组主要累及肺间质和肺泡腔,导致肺泡-毛细血管功能单位丧失的弥漫性肺疾病,因此早期诊断是有效管理ILD的关键.胸部高分辨率CT、肺功能检查、支气管镜及肺活检是诊断ILD和评估疾病严重程度及治疗效果的有效手段,但费用高、辐射多、侵袭性大.研究发现,肺泡Ⅱ型细胞表面抗原-6(KL-6)是ILD有前景的血清学指标,其与ILD的发生、进展、药物疗效及预后均有明显相关性,同时发现KL-6在其他呼吸系统疾病中也起着重要作用.本文就KL-6在呼吸系统疾病中的研究进展作一综述.
Interstitial lung disease ( ILD ) is a group of diffuse lung diseases that mainly affect the pulmonary interstitium and alveolar space , resulting in the loss of alveolar-capillary functional units ,so early diagnosis is the key to effective management of ILD .Thoracic high-resolution CT ,pulmonary function tests ,bronchoscopy and lung biopsy are effective means for diagnosis of ILD ,and can assess disease severity and treatment efficacy .But it is costly ,radiant and invasive .Studies have found that alveolar type Ⅱ cell surface antigen 6 ( KL-6 ) is a promising serological marker for ILD ,which is significantly associated with the occurrence ,progression ,drug efficacy and prognosis of ILD .It is also found that KL-6 also plays an important role in other respiratory diseases .This article reviews the research progress of KL-6 in respiratory diseases .